this article is republished from the conversation under a creative commons license. read the original article.
south africa reacted with outrage to travel bans , first triggered by the uk , imposed on it in the wake of the news that its genomics surveillance team had detected a new variant of the sars-cov-2 virus. the network for genomics surveillance in south africa has been monitoring changes in sars-cov-2 since the pandemic first broke out.
the new variant – identified as b.1.1.529 has been declared a variant of concern by the world health organisation and assigned the name omicron.
advertisement
the same was observed for the astrazeneca vaccine. despite not protecting against the mild-moderate beta covid in south africa, it still showed high levels of protection (80% effective) against hospitalisation due to the beta and gamma variants in canada.
firstly, don’t indiscriminately impose further restrictions, except on indoor gatherings. it was unsuccessful in reducing infections over the past 3 waves in south africa, considering 60%-80% people were infected by the virus based on sero-surveys and modelling data. at best, the economically damaging restrictions only spread out the period of time over which the infections took place by about 2-3 weeks.
advertisement
in addition, by the time the ban has been imposed, the variant will likely have already been spread. this is already evident from cases of omicron being reported from belgium in a person with no links to contact with someone from southern africa, as well as cases in israel, uk and germany.
advertisement
provide booster doses of j&j or pfizer to all adults who received a single dose j&j. it’s needed to increase protection against severe covid. a single dose of the j&j vaccine reduced hospitalisation due to delta variant in south africa by 62% in south african healthcare workers, whereas two doses of az and mrna vaccines in general had greater than 80%-90% protection against severe disease from the delta variant .
advertisement
the evidence is clear that the type of immune responses from a heterologous approach of az or jj followed by a mrna vaccines such as pfizer/biontech induces superior neutralising and cell mediated immune responses than two doses of the non-replicating vector vaccines.
advertisement
advertisement